Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing off-the-shelf cellular immunotherapies using its proprietary induced pluripotent stem cell (iPSC) product platform ⁶. The company's core business model involves creating and engineering human iPSCs to incorporate novel synthetic controls of cell function, generating clonal master iPSC lines, and then differentiating these lines to produce uniform T-cell and natural killer (NK) cell product candidates for therapeutic use ⁶. Revenue generation is primarily through research and development fees from collaborations and potential future milestone and royalty payments, as the company has not yet obtained regulatory approval for any product candidates or generated revenues from therapeutic product sales ⁶⁴. Primary customer segments, once products are approved, would include patients with autoimmune diseases and cancer ⁷. The company operates a 40,000+ square foot fully integrated Good Manufacturing Practice (GMP) facility in San Diego, California, intended to support all phases of clinical development and initial commercialization ⁷.

The company's pipeline includes several iPSC-derived CAR-targeted T-cell and NK cell product candidates. FT819 is an iPSC-derived, CD19-targeted CAR T-cell product candidate, currently in a multi-center Phase 1 clinical trial for moderate-to-severe Systemic Lupus Erythematosus (SLE), including lupus nephritis ⁷. This candidate incorporates a novel 1XX CAR construct inserted into the T-cell receptor (TCR) alpha chain (TRAC) locus and complete disruption of TCR expression to prevent graft-versus-host disease (GvHD) ¹⁰. FT819 received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA in April 2025 for moderate-to-severe SLE ⁷. As of an October 22, 2025 data cutoff, 10 treated SLE patients with ≥ 1 month follow-up showed progressive decreases in mean SLEDAI-2K scores, with DL1 decreasing from a mean of 15.2 (n=5) at baseline to 6 at month 6 (n=2), and DL2 decreasing from a mean of 14.3 (n=3) at baseline to 4 at month 6 (n=1) ¹⁰. No dose-limiting toxicities, Grade >2 CRS, ICANS, or GvHD were reported ¹².

FT825 is an iPSC-derived CAR T-cell product candidate for advanced solid tumors, developed in collaboration with Ono Pharmaceutical ¹³. It incorporates seven novel synthetic controls, including a HER2 binding domain designed to preferentially target tumor cells, a high-affinity hnCD16 Fc receptor, a synthetic IL-7/IL-7 receptor fusion, a synthetic CXCR2 receptor, a synthetic TGFβ receptor, and complete elimination of CD38 expression, along with TCR disruption for GvHD prevention ¹³. A Phase 1 clinical trial for FT825 in advanced solid tumors initiated in January 2024 is currently enrolling at the third dose level of 900 million cells as monotherapy and in combination with EGFR-targeted monoclonal antibody therapy ¹⁶.

FT836 is a multiplexed-engineered CAR T-cell product candidate targeting MICA and MICB proteins, designed to address challenges in treating solid tumors ¹⁶. It incorporates nine edits, including the hnCD16 Fc receptor and the novel Sword & Shield™ technology (ADR technology alongside CD58KO) to avoid the need for conditioning chemotherapy ¹⁷. The FDA allowed an IND for FT836 in July 2025 to initiate Phase 1 clinical investigation for solid tumors without conditioning chemotherapy ¹⁹. The first patient, a 47-year-old male with stage IV colorectal cancer, was treated in November 2025 at 300 million cells in the cetuximab combination arm without conditioning chemotherapy and received a second outpatient dose on Day 15 ¹⁹.

FT839 is a multi-antigen dual-CAR T-cell product candidate expressing two CARs targeting CD19 and CD38, incorporating 13 edits including CD3 Fusion Receptor, hnCD16, and Sword & Shield™ technology ¹⁹. IND-enabling activities are expected to be completed in 2026 to support initial clinical investigation for cancer and autoimmune diseases ²⁰. FT522 is an iPSC-derived CAR NK cell product candidate incorporating the novel Alloimmune Defense Receptor (ADR) technology, a proprietary CD19-targeted CAR, hnCD16 Fc receptor, an IL-15/IL-15 receptor fusion, and complete elimination of CD38 expression ²¹. A Phase 1 clinical trial for FT522 in relapsed/refractory B-cell lymphoma has been completed, showing no reported CRS or ICANS, and product detection in patients with and without conditioning chemotherapy ²². An IND application for FT522 in a basket of B cell-mediated autoimmune diseases has been allowed by the FDA ²².

For the fiscal year ended December 31, 2025, the company reported an accumulated deficit of $1.5 billion ⁶⁴. As of December 31, 2025, cash, cash equivalents, and investments totaled $205.1 million ⁶³. The company recorded a $13.4 million impairment charge against property and equipment and a $1.3 million impairment charge against the right-of-use asset in the statement of operations during the year ended December 31, 2024, due to a sustained decline in the trading price of common stock ⁸⁹.

During the reported period, Fate Therapeutics received RMAT designation for FT819 in SLE in April 2025 ⁷. The company also expanded its clinical investigation of FT819 into additional B cell-mediated autoimmune diseases (AAV, IIM, SSc) in February 2025, following an agreement with the FDA in December 2024 ⁸. In October 2025, the first SSc patient was treated with FT819 ¹³. An IND for FT522 for B cell-mediated autoimmune diseases was allowed by the FDA in October 2024 ⁸. The IND for FT836 for solid tumors was allowed in July 2025, and the first patient was treated in November 2025 ¹⁹. The collaboration with Ono Pharmaceutical was amended in June 2025, increasing aggregate estimated research and preclinical development fees payable by Ono for Candidate 3 by approximately $6.5 million, for a total estimated $44.5 million ²⁴. The company also announced a reduction in force affecting approximately 12% of its workforce on August 12, 2025, as part of a tactical operations plan to reduce costs and extend funding through the end of 2027 ⁷⁹.

Fate Therapeutics intends to continue the regulatory development of FT819 in Systemic Lupus Erythematosus (SLE), with plans to submit a Phase 2 registration-enabling clinical protocol in lupus nephritis and subsequently investigate its potential for extrarenal lupus in a second trial, aiming for a biologics license application (BLA) filing over the next several years ⁸. The company also plans to continue expanding its clinical investigation of FT819 outside of the United States in 2026, following authorizations from the MHRA in August 2025 and the EMA in October 2025 to initiate clinical trials in the U.K. and EU, respectively ⁸.

A major growth area for the company is the expansion of its iPSC product platform within the field of autoimmunity. Following an agreement with the FDA in December 2024, the clinical protocol for the Phase 1 trial of FT819 was amended in February 2025 to include three additional B cell-mediated autoimmune diseases: anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), idiopathic inflammatory myositis (IIM), and systemic sclerosis (SSc) ⁸. Dose-expansion cohorts have been initiated in SSc, AAV, and IIM, with the first SSc patient treated in October 2025 ⁸. The company believes this Phase 1 basket study approach offers a cost-effective and efficient pathway for broad clinical development in autoimmunity ⁸. Additionally, the company is evaluating opportunities and timelines for the clinical development of FT522, its CD19-targeted CAR NK cell product candidate, in autoimmune diseases, following the FDA's allowance of its IND application in October 2024 ⁸. FT522 incorporates Alloimmune Defense Receptor (ADR) technology, designed to reduce or eliminate the need for intense conditioning chemotherapy, which could enable a more favorable safety profile and treatment in community settings ⁸.

Another significant growth vector involves the design and development of off-the-shelf, multiplexed-engineered CAR T-cell immunotherapies for solid tumors. The company is advancing FT825, currently in Phase 1 clinical investigation in collaboration with Ono Pharmaceutical, which incorporates seven novel synthetic controls to overcome challenges in solid tumor treatment, including a HER2 binding domain designed for tumor-specific targeting ⁸. Furthermore, the company is developing FT836, a CAR T-cell product candidate targeting MICA and MICB proteins, which incorporates Sword & Shield™ technology to potentially enable treatment without conditioning chemotherapy ⁸. The IND for FT836 was allowed in July 2025, and the Phase 1 study is designed to assess its safety and activity without conditioning chemotherapy in combination with standard-of-care therapies ¹⁹. The company plans to provide an update on patients treated in the FT836 Phase 1 trial in the second half of 2026 ¹⁹. FT839, a dual-CAR T-cell product candidate targeting CD19 and CD38, is also undergoing IND-enabling activities in 2026 to support initial clinical investigation for cancer and autoimmune diseases ²⁰.

Operationally, the company is exploring the integration of novel synthetic controls of cell function into its iPSC product platform to enable off-the-shelf, iPSC-derived cell product candidates to be administered without intense conditioning chemotherapy and in community settings on an outpatient basis ⁹. This includes the Alloimmune Defense Receptor (ADR) technology and the knock-out of CD58, collectively referred to as Sword & Shield™ technology, which are incorporated into next-generation CAR T-cell programs like FT836 and FT839 ⁹. These technologies are designed to selectively recognize and destroy alloreactive host immune cells, maintain other components of the host immune system, and activate product candidates to enhance potency and persistence ⁹.

The company's planned capital allocation includes continued investment in research and development, particularly as it advances current product candidates in clinical trials and seeks to initiate clinical development for additional product candidates ⁶³. As of December 31, 2025, cash, cash equivalents, and investments were $205.1 million, which the company intends to use primarily for the advancement and clinical development of current product candidates, ongoing preclinical, discovery, and research programs, and for working capital and general corporate purposes ⁶³. The company also has an existing shelf registration statement under which it is eligible to issue an aggregate of approximately $220.0 million in securities, including $100.0 million issuable in "at the market offerings" ⁸⁷.

Management explicitly flagged several structural headwinds and execution risks to the growth plan. The development of product candidates will require substantial additional funding, and the company anticipates continued significant losses for the foreseeable future ⁶³, ⁶⁴. There is uncertainty in securing adequate funding on acceptable terms or on a timely basis, and any additional fundraising may cause dilution to stockholders or impose restrictive covenants if debt is incurred ⁶⁴. The regulatory approval process for novel product candidates like iPSC-derived therapies is particularly uncertain, and product candidates may fail to demonstrate the necessary safety, potency, durability, and efficacy ⁴⁶, ⁵⁶. Delays in initiating, conducting, or completing clinical trials are possible due to difficulties in patient recruitment, manufacturing adequate clinical supplies, or obtaining regulatory agreement on study design ⁴⁷. The manufacture and distribution of cell product candidates are complex and subject to risks, including cost increases and limitations on supply, and the FDA or foreign regulatory authorities may impose additional requirements ⁴⁹. The company also faces intense competition from other biotechnology and pharmaceutical companies in an environment of rapid technological change ⁴³, ⁷⁸.

Geographic, regulatory, and macro factors identified as constraints include differing regulatory requirements in foreign countries, unexpected changes in tariffs, trade barriers, price and exchange controls, and economic weakness or political instability in foreign economies and markets ⁶². Compliance with data privacy regulations in foreign countries, foreign taxes, and difficulties staffing and managing foreign operations are also noted ⁶². Global economic and market conditions, including inflationary pressures, interest rate fluctuations, and geopolitical tensions, could adversely impact the business, results of operations, and financial condition, and disrupt the supply chain ⁹⁰. The U.S. Supreme Court's 2024 decision in Loper Bright Enterprises v. Raimondo, which overruled the Chevron doctrine, may increase regulatory uncertainty and litigation risk, potentially delaying FDA regulatory review and policymaking ⁷⁷.

Management's overall tone emphasizes the company's pioneering approach in off-the-shelf cellular immunotherapies using its iPSC product platform, highlighting the potential for transformative treatments in autoimmune diseases and cancer. They stress the differentiation of their therapeutic approach, which aims to overcome limitations of current cell therapies by enabling mass production, uniformity, and off-the-shelf availability. A key strategic priority is to establish therapeutic differentiation with FT819 for Systemic Lupus Erythematosus (SLE), with and without lupus nephritis, and to pursue novel registrational strategies with the FDA under its RMAT designation, with the ultimate goal to advance to biologics license application (BLA) filing over the course of the next several years ⁸. A second strategic priority is to expand the clinical footprint of the iPSC product platform within the field of autoimmunity, including initiating clinical investigations of FT819 in additional B cell-mediated autoimmune diseases such as AAV, IIM, and SSc, and evaluating opportunities for FT522 in autoimmune diseases ⁸. The third strategic priority is to design and develop off-the-shelf, multiplexed-engineered CAR T-cell immunotherapies that incorporate multiple novel mechanisms of action for the treatment of solid tumors, exemplified by FT825, FT836, and FT839, with a focus on overcoming challenges like on-target, off-tumor toxicities and immunosuppression in the tumor microenvironment ⁸. Management also highlighted the tactical operations plan implemented on August 12, 2025, which included a reduction in force affecting approximately 12% of the workforce, intended to reduce costs and extend funding of operations through the end of 2027 ⁷⁹.

The company faces material risks including the potential failure of its novel iPSC-derived product candidates to demonstrate sufficient safety, potency, durability, and efficacy for regulatory approval or commercialization, particularly given the limited clinical experience with iPSC-derived and genome-edited therapies and the lower tolerance for adverse events in autoimmune disease populations ⁴⁶, ⁵¹, ⁵⁵. Development requires substantial additional funding, and the company's cash, cash equivalents, and investments of $205.1 million as of December 31, 2025, may not be sufficient, necessitating further equity or debt financings that could dilute stockholders or impose restrictive covenants ⁶³, ⁶⁴. Delays in clinical trials are a significant concern, stemming from difficulties in patient recruitment, manufacturing complexities, or regulatory disagreements on study design and endpoints ⁴⁷. The manufacturing of cell product candidates is complex, with risks of cost overruns, reproducibility issues, and reliance on sole-source suppliers for critical components, which could lead to supply limitations or increased costs ⁴⁹, ⁶⁶. The company is highly dependent on strategic partnerships, such as the one with Ono Pharmaceutical, and termination or unsuccessfulness of these arrangements could severely impact development and commercialization efforts and the receipt of up to $843.0 million in aggregate milestone payments ⁶⁵, ²⁴. Intense competition from other biotechnology and pharmaceutical companies, many with greater resources, poses a threat to market share and product differentiation ⁷⁸. Regulatory changes, such as the Inflation Reduction Act of 2022 and the One Big Beautiful Bill Act of 2025, could negatively impact drug pricing and reimbursement, while the U.S. Supreme Court's overruling of the Chevron doctrine may increase regulatory uncertainty and litigation risk ⁷⁶, ⁷⁷. Furthermore, the company is exposed to product liability claims, cybersecurity risks, and the potential for employee misconduct, which could result in significant financial and reputational harm ⁸⁰, ⁸⁴, ⁸¹. The company's ability to use its federal and state net operating loss carryforwards of $879.1 million and $773.3 million, respectively, may be limited by ownership changes, potentially increasing future tax liability ⁸⁹.